Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Autor: Eckmann J; Roche Innovation Center Munich, Germany., Fauti T; Roche Innovation Center Zurich, Switzerland., Biehl M; Roche Innovation Center Zurich, Switzerland., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Blanco L; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Lelios I; Roche Innovation Center Basel, Switzerland., Gottwald S; Roche Innovation Center Munich, Germany., Rae R; Roche Innovation Center Munich, Germany., Lechner S; Roche Innovation Center Munich, Germany., Bayer C; Roche Innovation Center Munich, Germany., Dekempe Q; Roche Innovation Center Munich, Germany., Osl F; Roche Innovation Center Munich, Germany., Carrié N; centre de recherche en cancérologie de toulouse INSERM U1037, toulouse, France., Kassem S; Centre de rechecrche en cancérologie de Toulouse de Inserm U1037, Toulouse, France., Lorenz S; Roche Innovation Center Munich, Germany., Christopeit T; Roche Innovation Center Munich, Germany., Carpy A; Roche Innovation Center Munich, Germany., Bujotzek A; Roche Innovation Center Munich, Germany., Bröske AE; Roche Innovation Center Munich, Germany., Dekhtiarenko I; Roche Innovation Center Zurich, Switzerland., Attig J; Pharmaceutical Sciences, pRED, Switzerland., Kunz L; Roche Innovation Center Zurich, Switzerland., Cremasco F; Roche Innovation Center Zurich, Switzerland., Adelfio R; Roche Innovation Center Zurich, Switzerland., Fertig G; Roche Innovation Center Munich, Germany., Dengl S; Roche Innovation Center Munich, Germany., Gassner C; Roche Innovation Center Munich, Germany., Bormann F; Roche Innovation Center Munich, Germany., Kirstenpfad C; Roche Innovation Center Munich, Germany., Kraft TE; Pharmaceutical Sciences, pRED, Germany., Diggelmann S; Roche Innovation Center Zurich, Switzerland., Knobloch M; Roche Innovation Center Munich, Switzerland., Hage C; Roche Innovation Center Munich, Germany., Feddersen R; Roche Innovation Center Munich, Germany., Heidkamp G; Roche Innovation Center Munich, Germany., Pöschinger T; Roche Innovation Center Munich, Germany., Mayoux ML; University of Zurich, Zurich, Switzerland., Bernasconi L; Lonza, Basel, Switzerland., Dumontet C; Hospices Civils de Lyon, Lyon, France., Prosper F; Clinica Universidad de Navarra, Pamplona, Spain., Martinet L; CRCT, Toulouse, France., Leclair S; Roche Innovation Center Munich, Germany., Xu W; METiS Pharmaceuticals, Hangzhou, China., Paiva B; Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC (CB16/12/00369), Pamplona, Spain., Klein C; Roche Innovation Center Zurich, Switzerland., Umaña P; Roche Innovation Center Zurich, Switzerland.

Publikováno v: Blood [Blood] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.